journal article·2013-07-10Open access

Preliminary Investigation of the Dissolution Behavior, Cytocompatibility, Effects of Fibrinogen Conformation and Platelet Adhesion for Radiopaque Embolic Particles

Sharon Kehoe, Marie-Laurence Tremblay, Aisling Coughlan, Mark Towler, Jan Rainey, Robert Abraham, Daniel Boyd

Abstract

Experimental embolic particles based on a novel zinc-silicate glass system have been biologically evaluated for potential consideration in transcatheter arterial embolization procedures. In addition to controlling the cytotoxicity and haemocompatibility for such embolic particles, its glass structure may mediate specific responses via dissolution in the physiological environment. In a 120 h in-vitro dissolution study, ion release levels for silicon (Si4+), sodium (Na+), calcium (Ca2+), zinc (Zn2+), titanium (Ti4+), lanthanum (La3+), strontium (Sr2+), and magnesium (Mg2+), were found to range from 0.04 to 5.41 ppm, 0.27–2.28 ppm, 2.32–8.47 ppm, 0.16–0.20 ppm, 0.12–2.15 ppm, 0.16–0.49 ppm and 0.01–0.12 ppm, respectively for the series of glass compositions evaluated. Initial release of Zn2+ (1.93–10.40 ppm) was only evident after 120 h. All compositions showed levels of cell viabilities ranging from 61.31 ± 4.33% to 153.7 ± 1.25% at 25%–100% serial extract dilutions. The conformational state of fibrinogen, known to induce thrombi, indicated that no changes were induced with respect of the materials dissolution by-products. Furthermore, the best-in-class experimental composition showed equivalency to contour PVA in terms of inducing platelet adhesion. The data generated here provides requisite evidence to continue to in-vivo pre-clinical evaluation using the best-in-class experimental composition evaluated.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Vascular Procedures and Complications · Intracranial Aneurysms: Treatment and Complications · Peripheral Artery Disease Management

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Applied Oral Sciences, Dalhousie University, PO Box 15000, Halifax, NS B3H 4R2, Canada

Department of Biochemistry & Molecular Biology, Dalhousie University, NS, B3H 4R2, Canada

Inamori School of Engineering, Alfred University, Alfred, NY 14802, USA

Faculty of Engineering & Architectural Science, Ryerson University, 350 Victoria Street, Toronto, ON, M5B 2K3, Canada

Department of Chemistry, Dalhousie University, NS B3H 4R2, Canada

Department of Diagnostic Imaging and Interventional Radiology, QE II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada

Room 3316, Halifax Infirmary Site 1796 Summer St., Halifax, NS, B3H 3A7, Canada

School of Biomedical Engineering, Dalhousie University, PO Box 15000, Halifax, NS B3H 4R2, Canada

References (62)

Show source-provided references
1. Hsu, C., Kwan, G., Thompson, S., Evans-Barns, H., and van Driel, M. (2012). Embolisation for pulmonary arteriovenous malformation. Cochrane Database Syst. Tev., 8.10.1002/14651858.CD008017.pub3 ↗
2. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study10.1007/s00270-009-9711-7 ↗
3. (2007). Uterine-artery embolization versus surgery for symptomatic uterine fibroids. N. Engl. J. Med., 356, 360–370.10.1056/NEJMoa062003 ↗
4. Symptomatic uterine fibroids: Treatment with uterine artery embolization or hysterectomy—Results from the randomized clinical Embolisation versus Hysterectomy (EMMY) Trial10.1148/radiol.2463070260 ↗
5. What evidence should we demand before accepting a new embolic material for uterine artery embolization?10.1016/j.jvir.2009.02.006 ↗
6. Spherical polyvinyl alcohol versus tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: Results of a limited randomized comparative study10.1097/01.RVI.0000179793.69590.1A ↗
7. (2009). Fatal nontarget embolization via an intrafibroid arterial venous fistula during uterine fibroid embolization. J. Vas. Interv. Radiol., 20, 419–420.10.1016/j.jvir.2008.12.412 ↗
8. Risk prediction of contrast-induced nephropathy10.1016/j.amjcard.2006.01.022 ↗
9. Contrast-induced acute kidney injury10.1016/j.jacc.2007.12.035 ↗
10. Epidemiology and prognostic implications of contrast-induced nephropathy10.1016/j.amjcard.2006.01.019 ↗
11. Radiopaque microspheres for improved transarterial chemical embolization (TACE)10.1016/j.jconrel.2011.08.132 ↗
12. Iodine-containing cellulose mixed esters as radiopaque polymers for direct embolization of cerebral aneurysms and arteriovenous malformations10.1016/S0142-9612(01)00087-4 ↗
13. In vitro assessment of EmboGel and UltraGel radiopaque hydrogels for the endovascular treatment of aneurysms10.1016/j.jvir.2009.01.005 ↗
14. A new injectable radiopaque chitosan-based sclerosing embolizing hydrogel for endovascular therapies10.1016/j.actbio.2012.04.006 ↗
15. Development of “imageable” beads for transcatheter embolotherapy10.1016/j.jvir.2010.02.031 ↗
16. Barium sulphate-loaded p(HEMA) microspheres as artificial emboli: Preparation and properties10.1016/0142-9612(90)90061-T ↗
17. Tantalum-loaded polyurethane microspheres for particulate embolization: Preparation and properties10.1016/0142-9612(91)90154-3 ↗
18. Novel radiopaque embolic agent for uterine fibroid embolization: Determination of radiopacity and biological evaluation; cytocompatibility, intracutaneous reactivity and local effects after implantation10.1016/j.jvir.2011.12.113 ↗
19. Kehoe, S., Langman, M., Zwanziger, U.W., Abraham, R.J., and Boyd, D. Mixture designs to assess composition–structure–property relationships in SiO2–CaO–ZnO–La2O3–TiO2–MgO–SrO–Na2O glasses: Potential materials for embolization. Available online:http://www.ncbi.nlm.nih.gov/pubmed/22863846.
20. (Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing within A Risk Management Process, 2009). Biological Evaluation of Medical Devices—Part 1: Evaluation and Testing within A Risk Management Process.
21. (Biological Evaluation of Medical Devices—Part 14: Identification and Quantification of Degradation Products from Ceramics, 2001). Biological Evaluation of Medical Devices—Part 14: Identification and Quantification of Degradation Products from Ceramics.
22. A preclinical study of the safety and efficacy of occlusinTM 500 artificial embolization device in sheep10.1007/s00270-011-0218-7 ↗
23. The relationship between platelet adhesion on surfaces and the structure versus the amount of adsorbed fibrinogen10.1016/j.biomaterials.2009.10.008 ↗
24. Adsorption and relaxation kinetics of albumin and fibrinogen on hydrophobic surfaces: Single-species and competitive behavior10.1021/la990089q ↗
25. Protein attachment on aluminosilicates surface studied by XPS and FTIR spectroscopy
26. Fibrinogen: Biochemistry, epidemology and determinants10.1093/qjmed/hcg129 ↗
27. Analysis of circular dichroism data10.1016/S0076-6879(04)83012-X ↗
28. Composition-structure-property (Zn2+ and Ca2+ ion release) evaluation of Si–Na–Ca–Zn–Ce glasses: Potential components for nerve guidance conduits10.1016/j.msec.2010.12.016 ↗
29. Experimental composite guidance conduits for peripheral nerve repair: An evaluation of ion release10.1016/j.msec.2012.04.058 ↗
30. Canine model of ischemic stroke with permanent middle cerebral artery occlusion: Clinical and histopathological findings10.4142/jvs.2007.8.4.369 ↗
31. Reversible middle cerebral-artery embolization in dogs without intracranial surgery10.1161/01.STR.20.10.1368 ↗
32. Partial splenic embolization with Y-shaped silicone particles10.1177/028418519403500405 ↗
33. Porous silicon in drug delivery devices and materials10.1016/j.addr.2008.03.017 ↗
34. Mesoporous carbon@silicon-silica nanotheranostics for synchronous delivery of insoluble drugs and luminescence imaging10.1016/j.biomaterials.2012.02.056 ↗
35. Effect of sodium-intake on ability of human-plasma to inhibit renal Na+-K+-adenosine triphosphatase in vitro10.1016/S0140-6736(81)91792-X ↗
36. Impact of uterine fibroid embolization with danazol alginate microsphere on ovarian function and subsequent pregnancy
37. Embolization agents-which one should be used when? Part 2: Small-vessel embolization10.1055/s-0030-1247891 ↗
38. An analytical model for the dissolution of different particle size samples of Bioglass((R)) in TRIS-buffered solution10.1016/j.biomaterials.2005.01.013 ↗
39. Weight loss, ion release and initial mechanical properties of a binary calcium phosphate glass fibre/PCL composite10.1016/j.actbio.2008.03.018 ↗
40. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by X-ray crystallography10.1074/jbc.274.8.4917 ↗
41. Review of medical physiology
42. Calcium-dependent unmasking of active-center cysteine during activation of fibrin stabilizing factor10.1021/bi00715a024 ↗
43. Transformation of cellular factor-XIII into an active zymogen transglutaminase in thrombin-stimulated platelets10.1055/s-0038-1653844 ↗
44. Serum titanium levels in individuals undergoing intramedullary femoral nailing with a titanium implant10.1097/01.ta.0000240445.20220.54 ↗
45. Plasma surface modification of titanium for hard tissue replacements10.1016/j.surfcoat.2004.02.045 ↗
46. Surface modification of titanium, titanium alloys, and related materials for biomedical applications10.1016/j.mser.2004.11.001 ↗
47. Thermal properties and devitrification behavior of (2.5–x)CaO center dot x/3La2O3•2SiO210.1016/S0040-6031(00)00364-6 ↗
48. Lanthanum citrate induces anoikis of Hela cells10.1016/j.canlet.2009.05.018 ↗
49. Influence of magnesia on the structure and properties of bioactive glasses10.1016/j.jnoncrysol.2009.04.074 ↗
50. Serum magnesium level; comparison between healthy and malnourished children
51. Haemocompatibility evaluation of DLC- and SiC-coated surfaces10.22203/eCM.v005a02 ↗
52. The history of biodegradable magnesium implants: A review10.1016/j.actbio.2010.02.028 ↗
53. Magnesium and cardiovascular system
54. Acute hypermagnesemia: A rare complication of antacid administration after bone marrow transplantation10.1016/S0009-8981(02)00308-X ↗
55. Dissolution behavior and bioactivity study of glass ceramic scaffolds in the system of CaO-P2O5-Na2O-ZnO prepared by sol-gel technique10.1016/j.msec.2009.09.006 ↗
56. In vitro and in vivo behaviour of zinc-doped phosphosilicate glasses10.1016/j.actbio.2008.07.007 ↗
57. The antibacterial effects of zinc ion migration from zinc-based glass polyalkenoate cements10.1007/s10856-006-8930-6 ↗
58. Zinc-containing bioactive glasses: Surface reactivity and behaviour towards endothelial cells10.1016/j.actbio.2008.10.020 ↗
59. The effect of ionic dissolution products of Ca-Sr-Na-Zn-Si bioactive glass on in vitro cytocompatibility10.1007/s10856-010-4139-9 ↗
60. In vitro bioactivity of novel tricalcium silicate ceramics10.1007/s10856-006-0069-y ↗
61. In vitro measurement of conformational stability of fibrinogen adsorbed on siloxane10.1021/bm040041d ↗
62. Platelet-rich plasma and fibrin glue-coated bioactive ceramics enhance growth and differentiation of goat bone marrow-derived stem cells10.1089/ten.tea.2008.0229 ↗